RSI Overbought Stocks
AVBP is RSI overbought, meaning strong buying pressure may lead to a short-term consolidation or pullback.
ARRIVENT BIOPHARMA INC (AVBP) Stock Price & Overview
NASDAQ:AVBP • US04272N1028
Current stock price
29.61 USD
+0.2 (+0.68%)
At close:
29.61 USD
0 (0%)
After Hours:
The current stock price of AVBP is 29.61 USD. Today AVBP is up by 0.68%. In the past month the price increased by 29.81%. In the past year, price increased by 63.23%.
AVBP Key Statistics
52-Week Range16.1 - 29.71
Current AVBP stock price positioned within its 52-week range.
1-Month Range20.72 - 29.71
Current AVBP stock price positioned within its 1-month range.
- Market Cap
- 1.309B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.41
- Dividend Yield
- N/A
AVBP Stock Performance
Today
+0.68%
1 Week
+8.66%
1 Month
+29.81%
3 Months
+41.95%
Longer-term
6 Months +51.77%
1 Year +63.23%
2 Years +79.24%
3 Years N/A
5 Years N/A
10 Years N/A
AVBP Stock Chart
AVBP Stock Screens
AVBP currently appears in the following ChartMill screener lists.
AVBP Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to AVBP. When comparing the yearly performance of all stocks, AVBP is one of the better performing stocks in the market, outperforming 89.62% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
AVBP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AVBP. AVBP has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
AVBP Earnings
Next Earnings DateMay 11, 2026
Last Earnings DateMar 5, 2026
PeriodQ4 / 2025
EPS Reported-$0.78
Revenue Reported
EPS Surprise 9.75%
Revenue Surprise %
AVBP Forecast & Estimates
19 analysts have analysed AVBP and the average price target is 43.58 USD. This implies a price increase of 47.19% is expected in the next year compared to the current price of 29.61.
Analysts
Analysts86.32
Price Target43.58 (47.18%)
EPS Next Y13.13%
Revenue Next YearN/A
AVBP Groups
Sector & Classification
AVBP Financial Highlights
Over the last trailing twelve months AVBP reported a non-GAAP Earnings per Share(EPS) of -4.41. The EPS decreased by -71.6% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-166.31M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.92% | ||
| ROE | -54.13% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-27.87%
Sales Q2Q%N/A
EPS 1Y (TTM)-71.6%
Revenue 1Y (TTM)N/A
AVBP Ownership
Ownership
Inst Owners89.67%
Shares44.20M
Float39.88M
Ins Owners2.92%
Short Float %19.47%
Short Ratio14.37
AVBP Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.09 | 369.653B | ||
| AMGN | AMGEN INC | 15.3 | 188.346B | ||
| GILD | GILEAD SCIENCES INC | 15.67 | 171.971B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.37 | 110.812B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.91 | 78.867B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.9 | 42.456B | ||
| INSM | INSMED INC | N/A | 30.821B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.581B | ||
| NTRA | NATERA INC | N/A | 27.795B | ||
| BIIB | BIOGEN INC | 10.92 | 25.833B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.86 | 25.444B | ||
| MRNA | MODERNA INC | N/A | 21.686B | ||
| INCY | INCYTE CORP | 12.32 | 18.97B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AVBP
Company Profile
Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, licensing, and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company is headquartered in Newtown Square, Pennsylvania and currently employs 77 full-time employees. The company went IPO on 2024-01-26. The firm is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations. The company is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 candidate is focused on the treatment of solid tumors.
Company Info
IPO: 2024-01-26
ARRIVENT BIOPHARMA INC
18 Campus Blvd., Suite 100
Newtown Square PENNSYLVANIA US
Employees: 77
Phone: 12407806356
ARRIVENT BIOPHARMA INC / AVBP FAQ
Can you describe the business of ARRIVENT BIOPHARMA INC?
Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, licensing, and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company is headquartered in Newtown Square, Pennsylvania and currently employs 77 full-time employees. The company went IPO on 2024-01-26. The firm is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations. The company is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 candidate is focused on the treatment of solid tumors.
What is the stock price of ARRIVENT BIOPHARMA INC today?
The current stock price of AVBP is 29.61 USD. The price increased by 0.68% in the last trading session.
What is the dividend status of ARRIVENT BIOPHARMA INC?
AVBP does not pay a dividend.
What is the ChartMill rating of ARRIVENT BIOPHARMA INC stock?
AVBP has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting AVBP stock to perform?
19 analysts have analysed AVBP and the average price target is 43.58 USD. This implies a price increase of 47.19% is expected in the next year compared to the current price of 29.61.
What is the employee count for AVBP stock?
ARRIVENT BIOPHARMA INC (AVBP) currently has 77 employees.